Skip to content

Oyster Point Pharma Goes Public

OIS INDEX Oyster Point

Oyster Point Pharma is now officially listed on the Nasdaq Global Market under “OYST.” Initial share pricing was $16; to date the stock’s high has been $19.01, while its low has been $15.16. Look for Oyster Point to join the OIS Index in the next report.

Oyster Point Pharma’s lead product candidate, OC-01, a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease.

SHARE THIS ARTICLE WITH YOUR COLLEAGUES:

RECOMMENDED FOR YOU

Soft CL slows myopia in children

Soft CL slows myopia in children

Lucentis and Eylea patent expirations in the micro-crystal ball

Lucentis and Eylea patent expirations in the micro-crystal ball

OIS Index Posts a Strong Finish to 2019

OIS Index Posts a Strong Finish to 2019

Innovations a Highlight at Dry Eye Breakout Session

Innovations a Highlight at Dry Eye Breakout Session

BioGenware’s Speculet Seeks to Improve the Patient Experience

BioGenware’s Speculet Seeks to Improve the Patient Experience

We’ve Got Your BAK

We’ve Got Your BAK

About The Author

Michelle Dalton

Michelle Dalton, ELS, is an award-winning journalist who founded Dalton & Associates Medical Writing in 2006. She has spent the past 17 years writing primarily about ophthalmology, covering everything from the business of ophthalmology to the latest in pharmacologic and technology advances.

SUBSCRIBE TO OUR NEWSLETTER

Get The Latest News In Opthalmologic Innovation To Your Inbox.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.
Scroll To Top